US Pharma MarketingRepligen’s deal for BioLife Solutions indicates shift to manufacturing integration
Repligen’s $1.5bn purchase of BioLife Solutions adds CryoStor biopreservation to its bioprocessing portfolio, underscoring pharma’s shift toward integrated cell and gene therapy supply chains.
Repligen’s $1.5bn purchase of BioLife Solutions adds CryoStor biopreservation to its bioprocessing portfolio, underscoring pharma’s shift toward integrated cell and gene therapy supply chains.
Source: Pharmaceutical Technology